| Philip Mcclure, MD | |
|
2222 Welborn St, Dallas, TX 75219-3924 | |
| (214) 559-5000 | |
| Not Available |
| Full Name | Philip Mcclure |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 15 Years |
| Location | 2222 Welborn St, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740418912 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XP3100X | Orthopaedic Surgery - Pediatric Orthopaedic Surgery | Q3047 (Texas) | Secondary |
| 207X00000X | Orthopaedic Surgery | 14552 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sinai Hospital Of Baltimore, Inc | 0941112346 | 333 |
News Archive
Patients with Parkinson's disease have an increased risk for mortality, especially if they have dementia, a meta-analysis confirms.
By combining nanoparticles with a scorpion venom compound already being investigated for treating brain cancer, University of Washington researchers found they could cut the spread of cancerous cells by 98 percent, compared to 45 percent for the scorpion venom alone.
State sponsors of the nationwide effort to block a government requirement to purchase health insurance today sent a letter to President Obama decrying their exclusion from tomorrow's bipartisan health reform summit.
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
› Verified 9 days ago
| Entity Name | Sinai Hospital Of Baltimore, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043235666 PECOS PAC ID: 0941112346 Enrollment ID: O20031104000353 |
News Archive
Patients with Parkinson's disease have an increased risk for mortality, especially if they have dementia, a meta-analysis confirms.
By combining nanoparticles with a scorpion venom compound already being investigated for treating brain cancer, University of Washington researchers found they could cut the spread of cancerous cells by 98 percent, compared to 45 percent for the scorpion venom alone.
State sponsors of the nationwide effort to block a government requirement to purchase health insurance today sent a letter to President Obama decrying their exclusion from tomorrow's bipartisan health reform summit.
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip Mcclure, MD 2222 Welborn St, Dallas, TX 75219-3924 Ph: (214) 559-5000 | Philip Mcclure, MD 2222 Welborn St, Dallas, TX 75219-3924 Ph: (214) 559-5000 |
News Archive
Patients with Parkinson's disease have an increased risk for mortality, especially if they have dementia, a meta-analysis confirms.
By combining nanoparticles with a scorpion venom compound already being investigated for treating brain cancer, University of Washington researchers found they could cut the spread of cancerous cells by 98 percent, compared to 45 percent for the scorpion venom alone.
State sponsors of the nationwide effort to block a government requirement to purchase health insurance today sent a letter to President Obama decrying their exclusion from tomorrow's bipartisan health reform summit.
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
› Verified 9 days ago
Dr. Christopher Michael Sakowski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7115 Greenville Ave Ste 310, Dallas, TX 75231 Phone: 214-265-3200 Fax: 214-265-3285 | |
Sumant G Krishnan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9301 N Central Expy, Suite 400, Dallas, TX 75231 Phone: 214-220-2468 Fax: 214-397-1555 | |
Jorge Casas, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 12222 N Central Expy, Suite 210, Dallas, TX 75243 Phone: 214-615-1949 Fax: 214-615-1949 | |
Nathan Bruck, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 411 N Washington Ave Ste 7000, Dallas, TX 75246 Phone: 214-823-7090 Fax: 214-823-1644 | |
Dr. Michael Wheeler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln Ste 130, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-750-8504 | |
Dr. Richard S Levy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6901 Snider Plz, Ste 200, Dallas, TX 75205 Phone: 214-369-7733 Fax: 214-360-9604 | |
Dr. Robert Russell Scheinberg, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln, Ste 130, Lb 11, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 |